Williams MS, Ng’alla LS.Heparin therapy leads to platelet activation and prolongation of PFA-100 closure time. J Cardiovasc Pharmacol Ther. 2005;10:273-280.
2.
Barradas MA, Mikhailidis DP, Epemolu O, Jeremy JY, Fonseca V, Dandona P.Comparison of the platelet pro-aggregatory effect of conventional unfractionated heparins and a low molecular weight heparin fraction (CY 222). Br J Haematol. 1987;67:451-457.
3.
Greenbaum RA, Barradas MA, Mikhailidis DP, Jeremy JY, Evans TR, Dandona P.Effect of heparin and contrast medium on platelet function during routine cardiac catheterisation. Cardiovasc Res. 1987;21:878-885.
4.
Jagroop IA, Barradas MA, Mikhailidis DP.A low molecular weight heparin, nadroparin (Fraxiparine), inhibits thrombin-induced platelet shape change and does not enhance spontaneous platelet aggregation. Br J Clin Pharmacol. 1996;41: 163-165.
5.
Mikhailidis DP, Barradas MA, Mikhailidis AM, Magnani H, Dandona P.Comparison of the effect of a conventional heparin and a low molecular weight heparinoid on platelet function. Br J Clin Pharmacol. 1984;17:43-48.
6.
Mikhailidis DP, Barradas MA, Jeremy JY, Gracey L, Wakeling A, Dandona P.Heparin-induced platelet aggregation in anorexia nervosa and in severe peripheral vascular disease. Eur J Clin Invest. 1985;15: 313-319.
7.
Mikhailidis DP, Barradas MA, Maris A, Jeremy JY, Dandona P.Fibrinogen mediated activation of platelet aggregation and thromboxane A2 release: pathological implications in vascular disease. J Clin Pathol. 1985;38: 1166-1171.
8.
Mikhailidis DP, Barradas MA, Dandona P.Heparin-induced platelet aggregation is inhibited by antagonists of the thromboxane pathway. Thromb Res. 1986;42: 719-720.
9.
Mikhailidis DP, Fonseca VA, Barradas MA, et al.Platelet activation following intravenous injection of a conventional heparin: absence of effect with a low molecular weight heparinoid (Org 10172). Br J Clin Pharmacol. 1987;24:415-424.
10.
Mikhailidis DP, Barradas MA, Mier A, et al.Platelet function in patients admitted with a diagnosis of myocardial infarction. Angiology. 1987;38:36-45.
11.
Grace AA, Barradas MA, Mikhailidis DP, et al.Cyclosporine A enhances platelet aggregation. Kidney Int. 1987;32:889-895.
12.
Barradas MA, Mikhailidis DP, Dandona P.The effect of non-esterified fatty acids on vascular ADP-degrading enzyme activity. Diabetes Res Clin Pract. 1987;3:9-19.
Mikhailidis DP, Mikhailidis AM, Woollard ML, Dandona P.Protection of prostacyclin-like activity in human plasma-a non-enzymatic mechanism?Clin Sci (Lond). 1982;62:177-181.
15.
Mikhailidis DP, Mikhailidis AM, Dandona P.Effect of human plasma proteins on stabilisation of platelet anti-aggregatory activity of prostacyclin. Ann Clin Biochem. 1982;19:241-244.
16.
Klinkhardt U, Graff J, Westrup D, et al.Pharmacodynamic characterization of the interaction between abciximab or tirofiban with unfractionated or a low molecular weight heparin in healthy subjects. Br J Clin Pharmacol. 2001;52: 297-305.
17.
Mohammed SF, Anderson WH, Smith JB, Chuang HY, Mason RG.Effects of heparin on platelet aggregation and release on thromboxane A2 production. Am J Pathol. 1981;104:132-141.
18.
Westwick J, Scully MF, Poll C, Kakkar VV.Comparison of the effects of low molecular weight heparin and unfractionated heparin on activation of human platelets in vitro. Thromb Res. 1986;42:435-447.
